Disclosed is the use of a ligand-targeted cationic liposome complex comprising a cationic liposome, a ligand which is an antibody or antibody fragment, one or more nucleic acid molecules encoding one or more viral proteins, and one or more nucleic acid molecules encoding one or more interleukins, wherein said antibody or antibody fragment is directly complexed with, but not chemically conjugated to, said cationic liposome, in the manufacture of an antigen presenting cell-targeted delivery medicament for use in treating a viral disease in a mammal in need thereof.
